Iovance Biotherapeutics has been granted a patent for improved methods to expand TILs for therapeutic use. The patent includes gene-editing techniques to enhance efficacy, reduce microbial contamination, and decrease costs. The gene-edited TIL composition includes silenced immune checkpoint genes PD-1 and TIGIT, leading to increased IFN-? secretion. GlobalData’s report on Iovance Biotherapeutics gives a 360-degree view of the company including its patenting strategy. Buy the report here.

Smarter leaders trust GlobalData


Data Insights Iovance Biotherapeutics Inc - Company Profile

Buy the Report

Data Insights

The gold standard of business intelligence.

Find out more

According to GlobalData’s company profile on Iovance Biotherapeutics, Cytokine activate T-cell based compositions was a key innovation area identified from patents. Iovance Biotherapeutics's grant share as of February 2024 was 18%. Grant share is based on the ratio of number of grants to total number of patents.

Gene-edited til composition with enhanced ifn-? secretion

Source: United States Patent and Trademark Office (USPTO). Credit: Iovance Biotherapeutics Inc

A recently granted patent (Publication Number: US11866688B2) discloses a gene-edited tumor infiltrating lymphocyte (TIL) composition designed for therapeutic purposes. The composition includes a therapeutic population of gene-edited TILs with silenced or reduced expression of immune checkpoint genes PD-1 and TIGIT, resulting in increased IFN-? secretion by at least five-fold compared to non-expanded TILs. The composition also contains a cryopreservant to maintain the viability of the gene-edited TILs.

Furthermore, the patent claims specify that the gene-edited TIL composition is capable of exhibiting IFN-? secretion greater than 1000 pg/ml, with the secretion levels measured in vitro using an enzyme-linked immunosorbent assay. The therapeutic population of gene-edited TILs is derived from TILs obtained from various cancer types, including melanoma, ovarian cancer, lung cancer, breast cancer, and others. The composition is intended to be cryopreserved for long-term storage and future therapeutic applications, highlighting its potential in cancer immunotherapy.

To know more about GlobalData’s detailed insights on Iovance Biotherapeutics, buy the report here.

Data Insights


The gold standard of business intelligence.

Blending expert knowledge with cutting-edge technology, GlobalData’s unrivalled proprietary data will enable you to decode what’s happening in your market. You can make better informed decisions and gain a future-proof advantage over your competitors.


GlobalData, the leading provider of industry intelligence, provided the underlying data, research, and analysis used to produce this article.

GlobalData Patent Analytics tracks bibliographic data, legal events data, point in time patent ownerships, and backward and forward citations from global patenting offices. Textual analysis and official patent classifications are used to group patents into key thematic areas and link them to specific companies